ERBB2 and breast cancer: Moreover, studies on HER2-negative BC suggest that HER2-low tumors generally achieve lower pCR rates compared to HER2-null tumors after NACT, although these differences do not always reach statistical significance in multivariable logistic regression analyses (2, 13, 22, 25, 30, 37, 38).